Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 1,629 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: In The Mix Clear all
Not listed Phase 3 Interventional Results available

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer

NCT00954174
View directory record Official record
Conditions
Mixed Mesodermal (Mullerian) Tumor, Ovarian Carcinosarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage I Ovarian Cancer AJCC v6 and v7, Stage IA Fallopian Tube Cancer AJCC v6 and v7, Stage IA Ovarian Cancer AJCC v6 and v7, Stage IA Uterine Sarcoma AJCC v7, Stage IB Fallopian Tube Cancer AJCC v6 and v7, Stage IB Ovarian Cancer AJCC v6 and v7, Stage IB Uterine Sarcoma AJCC v7, Stage IC Fallopian Tube Cancer AJCC v6 and v7, Stage IC Ovarian Cancer AJCC v6 and v7, Stage IC Uterine Sarcoma AJCC v7, Stage II Ovarian Cancer AJCC v6 and v7, Stage IIA Fallopian Tube Cancer AJCC v6 and v7, Stage IIA Ovarian Cancer AJCC V6 and v7, Stage IIA Uterine Sarcoma AJCC v7, Stage IIB Fallopian Tube Cancer AJCC v6 and v7, Stage IIB Ovarian Cancer AJCC v6 and v7, Stage IIB Uterine Sarcoma AJCC v7, Stage IIC Fallopian Tube Cancer AJCC v6 and v7, Stage IIC Ovarian Cancer AJCC v6 and v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIA Uterine Sarcoma AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIB Uterine Sarcoma AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IIIC Uterine Sarcoma AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7, Stage IVA Uterine Sarcoma AJCC v7, Stage IVB Uterine Sarcoma AJCC v7, Uterine Carcinosarcoma
Interventions
Carboplatin, Ifosfamide, Paclitaxel, Quality-of-Life Assessment
Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
532
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 346 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 30, 2026, 4:43 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Daily Protein Pacing Effects on HbA1c in Type 2 Diabetics

NCT05355090
View directory record Official record
Conditions
Type 2 Diabetes, HbA1c, Protein Intake
Interventions
PP
Dietary Supplement
Lead sponsor
Skidmore College
Other
Eligibility
30 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Saratoga Springs, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 30, 2026, 4:43 PM EDT
Active, not recruiting Phase 2 Interventional

Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)

NCT05120284
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
Dichloroacetate (DCA), Genotype
Drug · Genetic
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 30, 2026, 4:43 PM EDT
Terminated No phase listed Observational

Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant

NCT01077440
View directory record Official record
Conditions
Cancer Survivor, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Neuroblastoma, Testicular Germ Cell Tumor
Interventions
DNA analysis, polymerase chain reaction, flow cytometry, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 30, 2026, 4:43 PM EDT
Completed Phase 2 Interventional Results available

Study of Capecitabine to Treat Recurrent High Grade Gliomas

NCT00717197
View directory record Official record
Conditions
Malignant Glioma
Interventions
Capecitabine
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 30, 2026, 4:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism

NCT00761826
View directory record Official record
Conditions
Mixed Astigmatism
Interventions
MEL 80 Mixed Astigmatism Treatment
Device
Lead sponsor
Carl Zeiss Meditec, Inc.
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
5
States / cities
San Diego, California • Greenwood Village, Colorado • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 30, 2026, 4:43 PM EDT
Completed Not applicable Interventional

Precision Medicine Guided Treatment for Cancer Pain

NCT02664350
View directory record Official record
Conditions
Pain, CYP2D6 Polymorphism
Interventions
CYP2D6, Brief Pain Inventory-Short Form (BPI-SF), M.D. Anderson Symptom Inventory (MDASI), OPRM1
Genetic · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 120 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Gainesville, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2019 · Synced Oct 30, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

NCT04819776
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Iloperidone, Iloperidone Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
20
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Cerritos, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Oct 30, 2026, 4:43 PM EDT
Completed Not applicable Interventional

Meru Health Program for Cancer Patients With Depression and Anxiety

NCT05588622
View directory record Official record
Conditions
Depression, Anxiety
Interventions
Meru Health Program
Behavioral
Lead sponsor
Meru Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 30, 2026, 4:43 PM EDT
Terminated Not applicable Interventional

Serving Women Using Opioids During Pregnancy

NCT03552120
View directory record Official record
Conditions
Opioid Use, Pregnancy Related
Interventions
MORE, Supportive Psychotherapy
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 30, 2026, 4:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Soy as an Innovative Dietary Component in Abdominal Obesity Management Amongst Peri- and Early Menopausal Women

NCT02375113
View directory record Official record
Conditions
Central Obesity
Interventions
soy supplementation
Dietary Supplement
Lead sponsor
The University of Texas at San Antonio
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2024 · Synced Oct 30, 2026, 4:43 PM EDT
Completed Phase 3 Interventional Results available

Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

NCT01156142
View directory record Official record
Conditions
Head and Neck Cancer, Mucositis, Oral Complications of Radiation Therapy, Pain
Interventions
doxepin hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
120
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 77 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Oct 30, 2026, 4:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Estradiol Effects on Alcohol Across the Menstrual Cycle

NCT04595682
View directory record Official record
Conditions
Alcohol Use, Unspecified
Interventions
Placebo, Alcohol
Drug
Lead sponsor
Mark Fillmore
Other
Eligibility
21 Years to 35 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 30, 2026, 4:43 PM EDT
Enrolling by invitation Phase 4 Interventional

Periarticular Injection Versus Popliteal Block

NCT04575688
View directory record Official record
Conditions
Foot Surgery, Ankle Surgery
Interventions
Exparel, Bupivicaine
Drug
Lead sponsor
Campbell Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 30, 2026, 4:43 PM EDT
Completed Not applicable Interventional Results available

The SHUNT-V Study for Varices

NCT03583996
View directory record Official record
Conditions
Chronic Liver Disease
Interventions
HepQuant SHUNT Liver Diagnostic Test
Combination Product
Lead sponsor
HepQuant, LLC
Industry
Eligibility
18 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
26
States / cities
Chandler, Arizona • Coronado, California • Pasadena, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 30, 2026, 4:43 PM EDT
Terminated Phase 2 Interventional Results available

Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer

NCT00281879
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unusual Cancers of Childhood
Interventions
anti-thymocyte globulin, filgrastim, busulfan, carmustine, cyclophosphamide, cyclosporine, cytarabine, etoposide, fludarabine phosphate, melphalan, methotrexate, methylprednisolone, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Up to 60 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2017 · Synced Oct 30, 2026, 4:43 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mediators and Moderators of Auditory Training

NCT06812273
View directory record Official record
Conditions
Hearing Handicap
Interventions
STM Training, Speech Training, Mixed Training, Gamified Training, Foraging Training
Behavioral
Lead sponsor
Northeastern University
Other
Eligibility
18 Years to 85 Years
Enrollment
1,260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Riverside, California • Boston, Massachusetts • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 30, 2026, 4:43 PM EDT
Active, not recruiting Not applicable Interventional

Evaluating an Intervention to Prevent Overdoses in Rural and Urban Counties

NCT05463341
View directory record Official record
Conditions
Opiate Overdose, Fentanyl Overdose, Harm Reduction
Interventions
Fentanyl Test Strips
Behavioral
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 30, 2026, 4:43 PM EDT
Active, not recruiting Early Phase 1 Interventional

Tolerance Through Mixed Chimerism (Sip-Tego)

NCT06972069
View directory record Official record
Conditions
Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance, Immunosuppresion, Immunosuppression After Kidney Transplantation
Interventions
Combined Kidney/Bone Marrow Transplant, Donation of Kidney / Bone Marrow, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart)
Procedure · Drug
Lead sponsor
Tatsuo Kawai, MD, PhD
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 30, 2026, 4:43 PM EDT
Completed Phase 1 Interventional

Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

NCT04634539
View directory record Official record
Conditions
Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Interventions
Gemcitabine, Nab-paclitaxel, L-glutamine
Drug
Lead sponsor
Jun Gong, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Beverly Hills, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 30, 2026, 4:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Role of Flavanols In Cardiovascular Function in Healthy Aging

NCT01395277
View directory record Official record
Conditions
Aging
Interventions
High Flavanol first then Low Flavanol, Low Flavanol first then High Flavanol
Dietary Supplement
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2015 · Synced Oct 30, 2026, 4:43 PM EDT
Completed Not applicable Interventional

Effects of Soy Based Dietary Supplements on Cardiometabolic Risk Factors.

NCT02490683
View directory record Official record
Conditions
Obesity, Cardiovascular Risk Factors
Interventions
Luna Rich X, Placebo, Reliv Now
Dietary Supplement
Lead sponsor
Loma Linda University
Other
Eligibility
35 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 30, 2026, 4:43 PM EDT
Completed Not applicable Interventional Results available

Reducing the Transition From Acute to Chronic Musculoskeletal Pain Among Older Adults

NCT04118595
View directory record Official record
Conditions
Acute Musculoskeletal Pain, Chronic Pain
Interventions
Educational Video, Telecare, Correspondence with Primary Care Provider
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 30, 2026, 4:43 PM EDT
Completed Phase 2 Interventional

DMT310-001 Topical in the Treatment of Acne Vulgaris

NCT03536637
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DMT310, Hydrogen Peroxide, Placebo
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
San Diego, California • Saint Joseph, Missouri • Henderson, Nevada + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 30, 2026, 4:43 PM EDT